Chemotherapy for Patients With Locally Advanced Pancreatic Cancer (LAPC) With Additional Chemo-radiotherapy (CRT) for Patients With Borderline Resectable Tumours
Sponsored by Per Pfeiffer
About this trial
Last updated 5 years ago
Study ID
DPSG 2010-01
Status
Completed
Type
Interventional
Phase
Phase 2
Placebo
No
Accepting
18 to 75 Years
All
Not accepting
Healthy Volunteers
Trial Timing
Ended 7 years ago
What is this trial about?
Treating patients with initial local non-resectable pancreatic cancer with a combination
of oxaliplatin, irinotecan & 5-FU(FOLFIRINOX), consolidated with chemoradiotherapy in
potentially resectable patients, will result in a high rate of tumor shrinkage allowing
subsequent resection in patients with initial borderline resectable tumors and improved
overall survival for all patients.
What are the Participation Requirements?
Inclusion Criteria: (major)
- non-metastatic pancreatic cancer
- Performance status 0-1
- Bilirubin < 1.5 UNL
- Written informed consent
Exclusion Criteria: (major)
- no prior abdominal radiotherapy
- no prior chemotherapy for pancratic cancer
- no severe comorbidity
- patients must be able to undergo potential abdominal surgery